Expanding therapeutic implications, DORAs (e.g., daridorexant, lemborexant) show potential beyond insomnia for metabolic disorders, improving glucose tolerance in obesity models by blocking OX2R-driven overeating and SNS hyperactivity. Here, HCRTR2 is linked to Other metabolic disease.